Promising results for ocrelizumab in primary progressive MS
October 13, 2015Genentech, a biotechnology company owned by Roche Pharmaceuticals, has announced promising results from a phase III clinical trial of experimental therapy ocrelizumab in people with primary progressive MS. To read more, click on the link below:
Promising results for ocrelizumab in primary progressive MS
Article courtesy of MS Research Australia www.msra.org.au